-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson Halts DUPLEX-AD Trial for Atopic Dermatitis After Failing Efficacy Criteria

Reuters·12/26/2025 13:00:53

Please log in to view news